Surrozen (SRZN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
13 May, 2026Opening remarks and agenda
The meeting was called to order with directors, officers, employees, and auditors present via webcast or phone.
Voting procedures and meeting rules were outlined, with polls open until shortly after the meeting began.
Legal notice of the meeting was confirmed, and a quorum was established with at least one-third of outstanding shares represented.
Four agenda items were presented: election of directors, ratification of auditors, advisory vote on executive compensation, and advisory vote on compensation vote frequency.
Board and executive committee updates
Two nominees, Dr. Mace Rothenberg and Dr. David J. Woodhouse, were up for election as Class II directors to serve until the 2029 annual meeting.
Overview of voting outcomes
Both director nominees were elected to serve until the 2029 annual meeting or until successors are qualified.
Ernst & Young LLP was ratified as the independent registered public accounting firm for 2026.
Executive compensation as disclosed in the proxy statement was approved.
Stockholders preferred an annual advisory vote on executive compensation.
Final voting results will be filed with the SEC and maintained in corporate records.
Latest events from Surrozen
- Lead dual-mechanism therapy SZN-8141 enters trials, targeting major unmet needs in retinal disease.SRZN
Morgan Stanley 24th Annual Global Healthcare Conference - DUET study launches this year for a dual VEGF/Wnt therapy in DME, with initial data in 2027.SRZN
12th Annual Cantor Fitzgerald Global Healthcare Conference - Multifunctional antibodies targeting Wnt, VEGF, and IL-6 aim to transform retinal disease treatment.SRZN
Corporate presentation - Q2 2026 net income was $50.2M, with SZN-8141 IND and DUET trial milestones progressing.SRZN
Q2 2026 - Dual-targeting Wnt and VEGF therapies show synergistic efficacy in retinal disease models.SRZN
H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - SZN-8141 targets retinal diseases by combining Wnt agonism and VEGF inhibition for enhanced efficacy.SRZN
H.C. Wainwright 4th Annual BioConnect Investor Conference - Multi-functional antibodies targeting Wnt, VEGF, and IL-6 address major unmet needs in retinal disease.SRZN
Corporate presentation - Net loss widened to $127.5M as cash reached $106.9M; IND for SZN-8141 on track for H2 2026.SRZN
Q1 2026 - Annual meeting covers director elections, auditor ratification, and executive compensation votes.SRZN
Proxy filing